Xillix Technologies Corp

XLX-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about XLX-T

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
June 21, 2006
Small market cap of $15 million. Sales have not been as good as expected. Expected loss of $.04 in earnings in 2007.
Small market cap of $15 million. Sales have not been as good as expected. Expected loss of $.04 in earnings in 2007.
Robert McWhirter
President, Selective Asset Management
Price
$0.105
Owned
Unknown
DON'T BUY
DON'T BUY
December 8, 2005
Have got approval from FDA. Estimates have gone down the last 90 days because they hired a large sales staff, but sales are not appearing as quickly as hoped. Earnings are expected to get better for Dec/06, but are still negative going from -$0.08 to -$0.05. Looking out to ’07, they are expecting to earn $0.01.
Have got approval from FDA. Estimates have gone down the last 90 days because they hired a large sales staff, but sales are not appearing as quickly as hoped. Earnings are expected to get better for Dec/06, but are still negative going from -$0.08 to -$0.05. Looking out to ’07, they are expecting to earn $0.01.
Robert McWhirter
President, Selective Asset Management
Price
$0.240
Owned
Unknown
DON'T BUY
DON'T BUY
October 27, 2005
Has interesting technology that uses flourescent lighting to look inside the lungs re: early stage cancer. Ranks 678 out of 700 in the database, the bottom 10%. The market is waiting for sales to appear.
Has interesting technology that uses flourescent lighting to look inside the lungs re: early stage cancer. Ranks 678 out of 700 in the database, the bottom 10%. The market is waiting for sales to appear.
Robert McWhirter
President, Selective Asset Management
Price
$0.335
Owned
No
WAIT
WAIT
July 21, 2005
Have the FDA approval. The challenge in the recent quarter is that sales have been almost non-existant. Now ramping up their sales force which will be an increase in expenses. An excellent product, but a "wait and see" stock. Earnings may take a year, if not longer.
Have the FDA approval. The challenge in the recent quarter is that sales have been almost non-existant. Now ramping up their sales force which will be an increase in expenses. An excellent product, but a "wait and see" stock. Earnings may take a year, if not longer.
Robert McWhirter
President, Selective Asset Management
Price
$0.520
Owned
No
VAGUE
VAGUE
May 18, 2005
Waiting for the FDA approval and are fairly confidant they are going to get it. Just signed a marketing agreement with Conmed (CNMD-Q) which is an expert on high tech medical equipment. These 2 things should be a great impetus to put this company considerably higher.
Waiting for the FDA approval and are fairly confidant they are going to get it. Just signed a marketing agreement with Conmed (CNMD-Q) which is an expert on high tech medical equipment. These 2 things should be a great impetus to put this company considerably higher.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$0.600
Owned
No
DON'T BUY
DON'T BUY
April 14, 2005
Did a financing and have some cash. Earnings estimates are for losses, $0.06 in 2005 and $0.02 in 2006. Estimates have been shaved down by about 10% in the last 90 days. Next earnings are due to be reported in 2 weeks. Great product, but still waiting for approval.
Did a financing and have some cash. Earnings estimates are for losses, $0.06 in 2005 and $0.02 in 2006. Estimates have been shaved down by about 10% in the last 90 days. Next earnings are due to be reported in 2 weeks. Great product, but still waiting for approval.
Robert McWhirter
President, Selective Asset Management
Price
$0.640
Owned
No
BUY
BUY
March 23, 2005
Have a product for finding colon/lung cancer. The innovation in terms of product will be adopted by the industry.
Have a product for finding colon/lung cancer. The innovation in terms of product will be adopted by the industry.
Werner Muehelemann
Vice President and Senior Portfolio Manager, ING Funds
Price
$0.750
Owned
Yes
HOLD
HOLD
March 14, 2005
Hoping to get the FDA pre-market approval very soon and will be able to offer their flourescent device for early lung cancer detection. Interesting speculation.
Hoping to get the FDA pre-market approval very soon and will be able to offer their flourescent device for early lung cancer detection. Interesting speculation.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$0.760
Owned
No
WAIT
WAIT
February 11, 2005
Interesting technology. They use white light, which is the conventional lighting, for looking inside the body, but also their proprietory flourescent lighting. The challenge is that the company is expected to burn a bunch of cash. Will wait for the sales to start and earnings start to turn.
Interesting technology. They use white light, which is the conventional lighting, for looking inside the body, but also their proprietory flourescent lighting. The challenge is that the company is expected to burn a bunch of cash. Will wait for the sales to start and earnings start to turn.
Robert McWhirter
President, Selective Asset Management
Price
$0.800
Owned
No
BUY WEAKNESS
BUY WEAKNESS
January 13, 2005
Sold his position for tax loss reasons in December. Would like to get back in at around $0.70/0.75. A terrific company. Likes their technology. If they get FDA approval, he would expect a price of $1.85/2.00 in 12/24 months.
Sold his position for tax loss reasons in December. Would like to get back in at around $0.70/0.75. A terrific company. Likes their technology. If they get FDA approval, he would expect a price of $1.85/2.00 in 12/24 months.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$0.770
Owned
No
HOLD
HOLD
November 16, 2004
FDA gave a pass to proceed with the testing of Onco-Life, so not sure why the stock has not moved. Still likes.
FDA gave a pass to proceed with the testing of Onco-Life, so not sure why the stock has not moved. Still likes.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$0.700
Owned
Yes
VAGUE
VAGUE
September 2, 2004
It is special and interesting stock.
It is special and interesting stock.
Peter Brieger
Chairman & Chief Executive Officer, GlobeInvestment Capital Management
Price
$0.810
Owned
Yes
DON'T BUY
DON'T BUY
August 20, 2004
Has interesting technology. Ranks borderline 25% bottom part of the database. Earnings loss of $.11 improved to a loss of $.07 in 04 and $.02 for 05. Wait for FDA approval.
Has interesting technology. Ranks borderline 25% bottom part of the database. Earnings loss of $.11 improved to a loss of $.07 in 04 and $.02 for 05. Wait for FDA approval.
Robert McWhirter
President, Selective Asset Management
Price
$0.880
Owned
No
WEAK BUY
WEAK BUY
July 9, 2004
Intermediate buy signal. Has interesting technologies. Speculative.
Intermediate buy signal. Has interesting technologies. Speculative.
Robert McWhirter
President, Selective Asset Management
Price
$1.040
Owned
Yes
BUY
BUY
June 30, 2004
Expect there will be some news out in the next 3/6 months. Good technology. A viable business.
Expect there will be some news out in the next 3/6 months. Good technology. A viable business.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$0.950
Owned
Yes
Showing 1 to 15 of 28 entries